Overview

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response

Status:
Terminated

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the patients. To increase molecular response ratio we decided to increase imatinib dose to limited resistance to this drug and to add zoledronate for it anti tumoral activity to increase anti leukemic effect. We plan to accrue 37 patients in 5 centers. We will analyse molecular expression of BCR-ABL transcript after 6 months of treatment, safety, duration of response, VEGF expression and LTgd production.

Phase:

Phase 2

Details

Lead Sponsor:

Institut Bergonié

Collaborator:

Novartis

Treatments:

Diphosphonates
Imatinib Mesylate
Zoledronic acid